Kiromic BioPharma, Inc. Publishes Study in Journal of Biomedical Materials Research: Part B – Applied Biomaterials
Houston, Texas, Feb. 4, 2018 – Kiromic Inc., today announced that its scientific manuscript, entitled “Development of a M Cell-Targeted Microparticulate Platform For Oral Immunization Against the Ovarian Cancer Antigen, Sperm Protein 17”, will be published in the Journal of Biomedical Materials Research: Part B – Applied Biomaterials. The scientific manuscript describes the efficacy of the Kiromic BSK02-ODP platform in a murine model of advanced ovarian cancer.
About Kiromic Biopharma
Kiromic is a clinical-stage immunotherapy biopharmaceutical company with a breakthrough artificial intelligence drug discovery platform (KAI), and a focus on therapeutic development across multiple technology platforms; including cell therapy, TCR therapy, and CAR-T therapy, oral immunotherapy, and gene therapy.
Kiromic is committed to developing effective immunotherapeutics to improve outcomes and dramatically improve patient’s lives.
For more information, visit www.kiromic.com.
About Journal
The Journal of Biomedical Materials Research – Part B: Applied Biomaterials is a highly interdisciplinary peer-reviewed journal. The journal focuses on the application of biomaterials to the human body, and covers all disciplines where medical devices are used.
For more information, visit www.onlinelibrary.wiley.com/journal/10.1002/(ISSN)1552-4981.